Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanidatamab combinations in HER2-positive breast and gastric/GEJ cancer
CTR20210237Phase 2Completed
- Sponsor
- BeiGene
- Start
- Feb 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of zanidatamab in breast cancer, HER2-positive gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by BeiGene. Started Feb 2021; status: completed.
02
Drugs
zanidatamab
03
Conditions
breast cancerHER2-positive gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20210237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210237.